0.86%
54.91%
48.13%
33.90%
-1.66%
-33.24%
-67.08%
AI Spotlight on CGEN
Company Description
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe.The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer.Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets.
The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets.It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid.Compugen Ltd.
was incorporated in 1993 and is headquartered in Holon, Israel.
Market Data
| Last Price | 2.37 |
| Change Percentage | 0.86% |
| Open | 2.35 |
| Previous Close | 2.35 |
| Market Cap ( Millions) | 212 |
| Volume | 159735 |
| Year High | 3.03 |
| Year Low | 1.35 |
| M A 50 | 1.71 |
| M A 200 | 1.84 |
Financial Ratios
| FCF Yield | 0.00% |
| Dividend Yield | 0.00% |
| ROE | 2.62% |
| Debt / Equity | 4.87% |
| Net Debt / EBIDTA | -40.36% |
| Price To Book | 3.51 |
| Price Earnings Ratio | 132.71 |
| Price To FCF | 0 |
| Price To sales | 3.55 |
| EV / EBITDA | 19.66 |
News
- Jan -13 - Compugen initiated with bullish view at Oppenheimer, here's why
- Jan -08 - Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors
- Nov -27 - Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies
- Nov -12 - Compugen Ltd. (CGEN) Q3 2024 Earnings Call Transcript
- Nov -12 - Compugen (CGEN) Q3 Earnings and Revenues Lag Estimates
- Nov -12 - Compugen Reports Third Quarter 2024 Results
- Nov -11 - Compugen to Participate in Stifel 2024 Healthcare Conference
- Nov -05 - Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024
- Oct -29 - Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
- Oct -24 - Compugen Gears Up to Report Q3 Earnings: Here's What to Expect
- Oct -07 - Compugen to Present New Clinical Data at SITC 2024
- Sep -11 - Compugen (CGEN) Upgraded to Strong Buy: What Does It Mean for the Stock?
- Sep -09 - Compugen to Present at Single Cell Genomics 2024 Conference
- Aug -29 - Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Aug -26 - Can Compugen (CGEN) Run Higher on Rising Earnings Estimates?
- Aug -10 - Compugen Ltd. (CGEN) Q2 2024 Earnings Call Transcript
- Aug -06 - Compugen (CGEN) Reports Q2 Loss, Tops Revenue Estimates
- Aug -06 - Compugen Reports Second Quarter 2024 Results
- Jul -29 - Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors
- Jul -23 - Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Therapeutic Products
Expected Growth : 12.0 %
What the company do ?
Therapeutic Products from Compugen Ltd. are novel protein-based therapies for cancer and autoimmune diseases, utilizing its proprietary computational platforms.
Why we expect these perspectives ?
Compugen Ltd.'s Therapeutic Products segment growth of 12.0% is driven by increasing demand for immunotherapy and cancer treatments, strategic partnerships, and advancements in computational biology and AI-powered drug discovery. Additionally, growing investments in R&D and expanding product pipelines contribute to the segment's rapid growth.
Compugen Ltd. Products
| Product Range | What is it ? |
|---|---|
| IT Products | Compugen offers a wide range of IT products from leading manufacturers, including desktops, laptops, servers, storage, and networking equipment. |
| Managed Services | Compugen's managed services provide 24/7 monitoring, maintenance, and support for IT systems, ensuring maximum uptime and efficiency. |
| Cloud Services | Compugen offers a range of cloud services, including infrastructure as a service (IaaS), platform as a service (PaaS), and software as a service (SaaS). |
| Cybersecurity Solutions | Compugen's cybersecurity solutions provide advanced threat protection, vulnerability assessment, and incident response services. |
| Professional Services | Compugen's professional services provide expert consulting, implementation, and integration services for IT projects. |
| Data Center Solutions | Compugen's data center solutions provide design, build, and management services for data centers, including virtualization and consolidation. |
Compugen Ltd.'s Porter Forces
Threat Of Substitutes
The threat of substitutes for Compugen Ltd. is medium due to the presence of alternative IT solutions and services provided by other companies.
Bargaining Power Of Customers
The bargaining power of customers is high due to the large number of customers and the availability of alternative IT solutions, giving them the power to negotiate prices and services.
Bargaining Power Of Suppliers
The bargaining power of suppliers is low due to the company's strong relationships with its suppliers and the availability of alternative suppliers in the market.
Threat Of New Entrants
The threat of new entrants is medium due to the moderate barriers to entry in the IT industry, including the need for significant capital investment and expertise.
Intensity Of Rivalry
The intensity of rivalry is high due to the presence of several established players in the IT industry, leading to a competitive market with high rivalry among companies.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 2.02% |
| Debt Cost | 3.95% |
| Equity Weight | 97.98% |
| Equity Cost | 17.57% |
| WACC | 17.30% |
| Leverage | 2.06% |
Compugen Ltd. : Quality Control
Compugen Ltd. passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| GUBRA.CO | Gubra A/S operates as a biotech company with two primary areas of business: pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs. The CRO segment offers … |
| HYL.BR | Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health, oncology, women's health, and other major therapeutic areas. The company … |
| MDWD | MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a … |
| BIOA-B.ST | BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials … |
| BSLN.SW | Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Gubra
A-Score
1-Year Total Return ->
🥈
MediWound
A-Score
1-Year Total Return ->
🥉
Basilea Pharmaceutica
A-Score
1-Year Total Return ->
4
BioArctic
A-Score
1-Year Total Return ->
5
Compugen
A-Score
1-Year Total Return ->
6
